|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,287.00 GBX | +1.98% |
|
+2.07% | +6.67% |
| 06-03 | EARNINGS AND TRADING: Vaultz Capital ousts CEO Benz, promotes Wood | AN |
| 06-03 | The Biotech Growth Trust PLC Reports Earnings Results for the Full Year Ended March 31, 2026 | CI |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Gain (Loss) on Sale of Investment, Total (Rev) | -206M | -32.73M | 79.14M | -77.09M | 135M | |||||
Interest And Invest. Income (Rev) | 1.08M | 310K | 1.2M | 1.11M | 426K | |||||
Total Revenues | -205M | -32.42M | 80.35M | -75.98M | 135M | |||||
Gross Profit | -205M | -32.42M | 80.35M | -75.98M | 135M | |||||
Selling General & Admin Expenses, Total | -5.19M | 4.27M | 3.85M | 3.66M | 3.13M | |||||
Other Operating Expenses, Total | -5.19M | 4.27M | 3.85M | 3.66M | 3.13M | |||||
Operating Income | -200M | -36.69M | 76.5M | -79.64M | 132M | |||||
Interest Expense, Total | -175K | -792K | -1.12M | -1.32M | -1.14M | |||||
Net Interest Expenses | -175K | -792K | -1.12M | -1.32M | -1.14M | |||||
Currency Exchange Gains (Loss) | -2.34M | -3.76M | -621K | -1.55M | -461K | |||||
EBT, Excl. Unusual Items | -202M | -41.24M | 74.76M | -82.52M | 130M | |||||
EBT, Incl. Unusual Items | -202M | -41.24M | 74.76M | -82.52M | 130M | |||||
Income Tax Expense | 149K | 56K | 159K | 145K | 32K | |||||
Earnings From Continuing Operations | -202M | -41.3M | 74.6M | -82.66M | 130M | |||||
Net Income to Company | -202M | -41.3M | 74.6M | -82.66M | 130M | |||||
Net Income - (IS) | -202M | -41.3M | 74.6M | -82.66M | 130M | |||||
Net Income to Common Incl Extra Items | -202M | -41.3M | 74.6M | -82.66M | 130M | |||||
Net Income to Common Excl. Extra Items | -202M | -41.3M | 74.6M | -82.66M | 130M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -4.88 | -1.03 | 2.07 | -2.62 | 5.58 | |||||
Basic EPS - Continuing Operations | -4.88 | -1.03 | 2.07 | -2.62 | 5.58 | |||||
Basic Weighted Average Shares Outstanding | 41.44M | 40.29M | 36.04M | 31.51M | 23.34M | |||||
Net EPS - Diluted | -4.88 | -1.03 | 2.07 | -2.62 | 5.58 | |||||
Diluted EPS - Continuing Operations | -4.88 | -1.03 | 2.07 | -2.62 | 5.58 | |||||
Diluted Weighted Average Shares Outstanding | 41.44M | 40.29M | 36.04M | 31.51M | 23.34M | |||||
Normalized Basic EPS | -3.05 | -0.64 | 1.3 | -1.64 | 3.49 | |||||
Normalized Diluted EPS | -3.05 | -0.64 | 1.3 | -1.64 | 3.49 | |||||
Supplemental Items | ||||||||||
EBITA | -200M | -36.69M | 76.5M | -79.64M | 132M | |||||
EBIT | -200M | -36.69M | 76.5M | -79.64M | 132M | |||||
Effective Tax Rate - (Ratio) | -0.07 | -0.14 | 0.21 | -0.18 | 0.02 | |||||
Current Domestic Taxes | - | 17K | - | - | - | |||||
Current Foreign Taxes | 149K | 39K | 159K | 145K | 32K | |||||
Total Current Taxes | 149K | 56K | 159K | 145K | 32K | |||||
Normalized Net Income | -126M | -25.78M | 46.72M | -51.57M | 81.43M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 70K | 68K | 71K | 86K | 84K | |||||
Selling and Marketing Expenses | 70K | 68K | 71K | 86K | 84K | |||||
General and Administrative Expenses | -6M | 3.53M | 3.07M | 2.87M | 2.41M |
- Stock Market
- Stocks
- BIOG Stock
- Financials The Biotech Growth Trust PLC
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















